Glutamate Dehydrogenase Inhibitor Screening Kit (Fluorometric)

Glutamate Dehydrogenase Inhibitor Screening Kit (Fluorometric)is available at Gentaur for Next week Delivery.

for high-throughput screening of GDH inhibitors.

Description:

Glutamate dehydrogenase (GDH) (1.4.1.2) is a hexameric enzyme that catalyzes the reversible conversion of glutamate to α-ketoglutarate and ammonia while reducing NAD+ to NADH. Glutamate can be converted to α-ketoglutarate by GDH and then fluxed into the TCA cycle where it can be used to support oxidative phosphorylation, production of lipids, or to replenish key intermediates such as oxaloacetate. It is a key enzyme in the glutamine metabolic pathway. Overexpression of GDH has been shown to promote cell proliferation, migration and invasion in several tumors such as colorectal cancer. The increased reliance on glutamine metabolism makes GDH a target for therapeutic intervention in cancer. GDH inhibitors have been shown to be toxic for cancer cells in vitro. In BioVision’s Glutamate Dehydrogenase inhibitor screening Kit, Glutamate is deaminated by GDH producing NADH, which converts a non-fluorescent probe to a fluorescent product in the presence of enzyme mix that is detected fluorometrically at Ex/Em = 535/587 nm. The kit provides a rapid, simple, sensitive plate based test, which is also suitable for high-throughput screening of GDH inhibitors.

Applications:

Sample Typ:e

Alternate Name: Glutamate Dehydrogenase Assay Kit, Glutamate Dehydrogenase Inhibitor Screening Kit, Glutamate Dehydrogenase Inhibitor Assay Kit, Glutamate Dehydrogenase Inhibitor Fluorometric Screening Kit, Glutamate Dehydrogenase Inhibitor Kit, Glutamate Dehydrogenase Inhibitor Screening Assay, Glutamate Dehydrogenase Fluorometric Inhibitor Screening Kit, Glutamate Dehydrogenase Inhibitor Screening Kit (Fluorometric), Glutamate Dehydrogenase Kit, Glutamate Dehydrogenase Inhibitor Assay

Features and Benefits:

Simple, Sensitive plate based test, which is also suitable for high-throughput screening of GDH inhibitors, Rapid